Adalvo recently announced the successful closure on their DCP procedure (decentralized procedure for the European Union) for Icatibant development, a complex injectable peptide product. Icatibant, a selective and competitive bradykinin B2 receptor antagonist, is used to treat acute attacks of hereditary angioedema (HAE), a serious orphan disease. Icatibant is truly a landmark product and this DCP registration procedure was submitted within almost all the EU region. This product is an equivalent and more affordable version of Firazyr, providing more access to patients worldwide. Providing complex peptide synthesis expertise, AmbioPharm was a strategic partner and close collaborator in the development of this product.